U2AF1 and myeloid neoplasm: Spliceosome mutations, such as SRSF2, U2AF1, and ZRSR2, are adverse prognostic features typically associated with secondary AML [147] and are relatively common in myeloid neoplasms [148,149], making the spliceosome an attractive drug target.